Antonios Douros1, Sophie Dell'Aniello1, Golsa Dehghan1, Jean-François Boivin1, Christel Renoux2. 1. From the Centre for Clinical Epidemiology (A.D., S.D., G.D., J.-F.B., C.R.), Lady Davis Institute, Jewish General Hospital; Department of Epidemiology, Biostatistics, and Occupational Health (A.D., C.R., J.-F.B.) and Department of Neurology and Neurosurgery (C.R.), McGill University, Montreal, Québec, Canada; and Institute of Clinical Pharmacology and Toxicology (A.D.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany. 2. From the Centre for Clinical Epidemiology (A.D., S.D., G.D., J.-F.B., C.R.), Lady Davis Institute, Jewish General Hospital; Department of Epidemiology, Biostatistics, and Occupational Health (A.D., C.R., J.-F.B.) and Department of Neurology and Neurosurgery (C.R.), McGill University, Montreal, Québec, Canada; and Institute of Clinical Pharmacology and Toxicology (A.D.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany. christel.renoux@mcgill.ca.
Abstract
OBJECTIVE: To assess whether use of antidepressants with strong inhibition of serotonin reuptake is associated with a decreased incidence of ischemic stroke and myocardial infarction (MI). METHODS: We conducted a cohort study using the UK Clinical Practice Research Datalink and considering new users of selective serotonin reuptake inhibitors (SSRIs) or third-generation antidepressants who were ≥18 years of age between 1995 and 2014. Using a nested case-control approach, we matched each case of a first ischemic stroke or MI identified during follow-up with up to 30 controls on age, sex, calendar time, and duration of follow-up. We estimated incidence rate ratios (RRs) and 95% confidence intervals (CIs) of each outcome associated with current use of strong compared with weak inhibitors of serotonin reuptake using conditional logistic regression. RESULTS: The cohort included 938,388 incident users of SSRIs (n = 868,755) or third-generation antidepressants (n = 69,633). Mean age at cohort entry was 46 years (64% women). During follow-up, 15,860 cases of ischemic stroke and 8,626 cases of MI were identified and matched to 473,712 and 258,022 controls, respectively. Compared with current use of weak inhibitors of serotonin reuptake, current use of strong inhibitors was associated with a decreased rate of ischemic stroke (RR 0.88, 95% CI 0.80-0.97), but the effect size was smaller in some sensitivity analyses. The rate of MI was similar between strong and weak inhibitors (RR 1.00, 95% CI 0.87-1.15). CONCLUSION: Our large population-based study suggests that antidepressants strongly inhibiting serotonin reuptake may be associated with a small decrease in the rate of ischemic stroke.
OBJECTIVE: To assess whether use of antidepressants with strong inhibition of serotonin reuptake is associated with a decreased incidence of ischemic stroke and myocardial infarction (MI). METHODS: We conducted a cohort study using the UK Clinical Practice Research Datalink and considering new users of selective serotonin reuptake inhibitors (SSRIs) or third-generation antidepressants who were ≥18 years of age between 1995 and 2014. Using a nested case-control approach, we matched each case of a first ischemic stroke or MI identified during follow-up with up to 30 controls on age, sex, calendar time, and duration of follow-up. We estimated incidence rate ratios (RRs) and 95% confidence intervals (CIs) of each outcome associated with current use of strong compared with weak inhibitors of serotonin reuptake using conditional logistic regression. RESULTS: The cohort included 938,388 incident users of SSRIs (n = 868,755) or third-generation antidepressants (n = 69,633). Mean age at cohort entry was 46 years (64% women). During follow-up, 15,860 cases of ischemic stroke and 8,626 cases of MI were identified and matched to 473,712 and 258,022 controls, respectively. Compared with current use of weak inhibitors of serotonin reuptake, current use of strong inhibitors was associated with a decreased rate of ischemic stroke (RR 0.88, 95% CI 0.80-0.97), but the effect size was smaller in some sensitivity analyses. The rate of MI was similar between strong and weak inhibitors (RR 1.00, 95% CI 0.87-1.15). CONCLUSION: Our large population-based study suggests that antidepressants strongly inhibiting serotonin reuptake may be associated with a small decrease in the rate of ischemic stroke.
Authors: James F Meschia; Cheryl Bushnell; Bernadette Boden-Albala; Lynne T Braun; Dawn M Bravata; Seemant Chaturvedi; Mark A Creager; Robert H Eckel; Mitchell S V Elkind; Myriam Fornage; Larry B Goldstein; Steven M Greenberg; Susanna E Horvath; Costantino Iadecola; Edward C Jauch; Wesley S Moore; John A Wilson Journal: Stroke Date: 2014-10-28 Impact factor: 7.914
Authors: Søren Bak; Ioannis Tsiropoulos; Jens Ole Kjaersgaard; Morten Andersen; Erling Mellerup; Jesper Hallas; Luis Alberto García Rodríguez; Kaare Christensen; David Gaist Journal: Stroke Date: 2002-06 Impact factor: 7.914
Authors: Sebastian Schneeweiss; Jeremy A Rassen; Robert J Glynn; Jerry Avorn; Helen Mogun; M Alan Brookhart Journal: Epidemiology Date: 2009-07 Impact factor: 4.822
Authors: Victor M Castro; Patience J Gallagher; Caitlin C Clements; Shawn N Murphy; Vivian S Gainer; Maurizio Fava; Jeffrey B Weilburg; Susanne E Churchill; Isaac S Kohane; Dan V Iosifescu; Jordan W Smoller; Roy H Perlis Journal: BMJ Open Date: 2012-03-30 Impact factor: 2.692
Authors: Grace M Turner; Christel McMullan; Olalekan Lee Aiyegbusi; Danai Bem; Tom Marshall; Melanie Calvert; Jonathan Mant; Antonio Belli Journal: Int J Stroke Date: 2021-04-04 Impact factor: 5.266
Authors: Joseph Grech; Melissa Victoria Chan; Chinedu Ochin; Amber Lachapelle; Florian Thibord; Zoe Schneider; Bongani Brian Nkambule; Paul Charles John Armstrong; Catherine Wallace de Melendez; Katherine L Tucker; Mahdi Garelnabi; Timothy David Warner; Ming-Huei Chen; Andrew Danner Johnson Journal: Clin Pharmacol Ther Date: 2022-01-10 Impact factor: 6.903